Related Experiment Video

Updated: Jun 22, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression

Zhipeng Wang1, Haifeng Jin, Ruodan Xu

  • 1Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, Shaanxi Province 710032, China.

Experimental & Molecular Medicine
|June 30, 2009
PubMed

Insights

Triptolide, derived from Tripterygium wilfordii, shows promise in preventing colon cancer progression. This compound reduces inflammation and inhibits tumor formation by targeting key cellular pathways.

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Background:

  • Triptolide is a compound from Tripterygium wilfordii with potential anti-tumor and anti-autoimmune properties.
  • Colorectal cancer (CRC) development is often preceded by chronic inflammation like colitis.
  • Understanding triptolide's mechanism in preventing colitis-induced CRC is crucial.

Purpose of the Study:

  • To investigate triptolide's efficacy in preventing the progression from colitis to colon cancer.
  • To elucidate the molecular mechanisms underlying triptolide's anti-cancer effects.

Main Methods:

  • A mouse model of colitis-induced colorectal cancer was utilized.
  • In vitro assays assessed colon cancer cell proliferation, migration, and colony formation.
  • Molecular analysis targeted the IL6R-JAK/STAT pathway, Rac1 activity, and cell cycle regulators.

Main Results:

  • Triptolide treatment reduced colon cancer incidence and increased survival rates in mice.
  • Dose-dependent inhibition of tumor formation was observed in nude mice xenografts.
  • In vitro, triptolide suppressed colon cancer cell proliferation, migration, and colony formation.
  • Triptolide decreased IL6 secretion, JAK1, IL6R, and phosphorylated STAT3 levels.
  • Triptolide inhibited Rac1 activity, blocked cyclin D1 and CDK4 expression, inducing G1 arrest.

Conclusions:

  • Triptolide effectively prevents colitis-induced colon cancer progression in a mouse model.
  • The compound acts by interrupting the IL6R-JAK/STAT pathway, reducing inflammation and inhibiting tumor cell proliferation and survival.
  • Triptolide demonstrates potential as a therapeutic agent for preventing colon cancer development, particularly in inflammatory contexts.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...